Myia Labs, ACC Join Forces For Congressional Healthcare Innovation Caucus Showcase

ACC Executive Vice President Brendan Mullen and Myia Labs Inc. Chief Executive Officer Simon MacGibbon were selected to participate in a Congressional Healthcare Innovation Caucus Showcase, held March 7 in the Rayburn House Office Building.

Designed for both clinicians and their patients, Myia's intelligent health monitoring platform ingests biometric patient data from curated sensors and transforms it into actionable clinical insights. Since the College's 2018 investment in Myia, the two partners have collaborated to develop the technology through a co-design approach and incorporate the platform into clinical workflow.

"We are proud to be collaborating with the ACC to set a new standard for creating technology that centers clinicians and patients," said MacGibbon. "We believe that health technology, when developed together with key stakeholders, can increase access and materially contribute to the realization of outcome and cost aspirations for value-based care."

The Myia platform equips clinicians with precise information to optimize care and stage preventative interventions. For patients with chronic and post-operative conditions, like heart failure, Myia sets a new bar for quality of life by helping stable patients remain at home, while flagging patients with signs of clinical decompensation for immediate intervention.

"We believe in the Myia team and their technology because they focus on using advanced processing technologies to make the life of the patient and the physician easier," said Mullen. "Cardiovascular medicine is already hard enough. The next generation of breakthroughs will come from leveraging technology to simplify the process of providing customized treatments for patients."

Through this showcase, Mullen and MacGibbon will have the opportunity to present Myia's health monitoring platform to members of Congress and their staff.

"It is exciting that the U.S. Congress is taking a strong, bipartisan interest in digital health," said John Rumsfeld, MD, FACC, ACC's Chief Innovation Officer. "It is even more exciting that the ACC and Myia were chosen for this opportunity to show that the successful development of digital health technologies relies on partnership between the technological and clinical worlds. The event also serves as another example of ACC Innovation taking a leadership role in the development and implementation of digital technologies to improve cardiovascular care and outcomes."

Learn more about ACC's Innovation efforts and join the College's Health Care Innovation Section at Don't miss special topic sessions at ACC.19 focused on evaluating disruptive technology in a value-based world and the potential of artificial intelligence in cardiovascular care.

Clinical Topics: Heart Failure and Cardiomyopathies, Acute Heart Failure

Keywords: ACC Advocacy, Biomedical Technology, Technology Assessment, Biomedical, Delivery of Health Care, Investments, Artificial Intelligence, Heart Failure

< Back to Listings